Expert Review of Anti-infective Therapy最新文献_第8页

Diagnosing fungal infections in clinical practice: a narrative review. 临床实践中的真菌感染诊断：综述。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-13 DOI: 10.1080/14787210.2024.2403017

Sarah Sedik,Stella Wolfgruber,Martin Hoenigl,Lisa Kriegl

{"title":"Diagnosing fungal infections in clinical practice: a narrative review.","authors":"Sarah Sedik,Stella Wolfgruber,Martin Hoenigl,Lisa Kriegl","doi":"10.1080/14787210.2024.2403017","DOIUrl":"https://doi.org/10.1080/14787210.2024.2403017","url":null,"abstract":"BACKGROUNDInvasive fungal infections (IFI) present a major medical challenge, with an estimated 6.5 million cases annually, resulting in 3.8 million deaths. Pathogens such as Aspergillus spp. Candida spp. Mucorales spp. Cryptococcus spp. and other fungi species contribute to these infections, posing risks to immunocompromised individuals. Early and accurate diagnosis is crucial for effective treatment and better patient outcomes.AREAS COVEREDThis narrative review provides an overview of the current methods and challenges associated with diagnosing fungal diseases including invasive aspergillosis, invasive candidiasis as well as rare and endemic fungal infections. Various diagnostic techniques, including microscopy, culture, molecular diagnostics, and serological tests, are reviewed, highlighting their respective advantages and limitations and role in clinical guidelines. To illustrate, the need for improved diagnostic strategies to overcome existing challenges, such as the low sensitivity and specificity of current tests and the time-consuming nature of traditional culture-based methods, is addressed.EXPERT OPINIONCurrent advancements in fungal infection diagnostics have significant implications for healthcare outcomes. Improved strategies like molecular testing and antigen detection promise early detection of fungal pathogens, enhancing patient management. Challenges include global access to advanced technologies and the need for standardized, user-friendly point-of-care diagnostics to improve diagnosis of fungal infections globally.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":"19 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142262038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunomodulatory markers and therapies for the management of infant respiratory syncytial virus infection 治疗婴儿呼吸道合胞病毒感染的免疫调节标记物和疗法

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-13 DOI: 10.1080/14787210.2024.2403147

Ricardo A. Loaiza, Mónica A. Farías, Catalina A. Andrade, Mario A. Ramírez, Linmar Rodriguez-Guilarte, José T. Muñóz, Pablo A. González, Susan M. Bueno, Alexis M. Kalergis

引用次数: 0

Anti-infective therapies for Pythium insidiosum keratitis. 脓疱疮性角膜炎的抗感染疗法。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-13 DOI: 10.1080/14787210.2024.2403146

Bharat Gurnani,Kirandeep Kaur

{"title":"Anti-infective therapies for Pythium insidiosum keratitis.","authors":"Bharat Gurnani,Kirandeep Kaur","doi":"10.1080/14787210.2024.2403146","DOIUrl":"https://doi.org/10.1080/14787210.2024.2403146","url":null,"abstract":"INTRODUCTIONPythium insidiosum keratitis (PIK) is a rapidly progressing ocular disease predominantly found in tropical and subtropical regions. Characterized by severe corneal damage and high morbidity, this infection poses significant challenges in diagnosis and management, necessitating effective anti-infective therapies.AREAS COVEREDThis report delves into the pathophysiology, clinical and microbiological diagnosis, and detailed insights into the anti-infective therapy for PIK, outlining current diagnostic challenges that complicate treatment. We review existing anti-infective therapies, including their efficacy and limitations, and discuss the role of surgical interventions in managing advanced cases. The report also highlights ongoing research into novel treatment approaches and the critical need for developing targeted therapies.EXPERT OPINIONDespite advances in understanding PIK, treatment remains complex due to pathogen resistance and diagnostic hurdles. Future research should focus on innovative anti-infective strategies, improved diagnostic techniques, and global surveillance to enhance therapeutic outcomes. Collaboration between ophthalmologists, microbiologists, and pharmacologists is essential to advance treatment protocols and improve patient prognosis.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":"188 1","pages":"1-13"},"PeriodicalIF":5.7,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142262037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of eravacycline (ERV) in treating infections caused by Gram-negative pathogens: a systematic review and meta-analysis. 依拉维辛（ERV）治疗革兰氏阴性病原体感染的有效性和安全性：系统综述和荟萃分析。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-11 DOI: 10.1080/14787210.2024.2397663

Zehua Chen,Weijia Sun,Yulong Chi,Beibei Liang,Yun Cai

{"title":"Efficacy and safety of eravacycline (ERV) in treating infections caused by Gram-negative pathogens: a systematic review and meta-analysis.","authors":"Zehua Chen,Weijia Sun,Yulong Chi,Beibei Liang,Yun Cai","doi":"10.1080/14787210.2024.2397663","DOIUrl":"https://doi.org/10.1080/14787210.2024.2397663","url":null,"abstract":"BACKGROUNDEravacycline (ERV) is a novel synthetic fluorocycline antibiotic with broad-spectrum antibacterial efficacy against pathogens. This study sought to investigate ERV's effectiveness and safety in treating Gram-negative pathogens (GNPs) infections.METHODSWe conducted a comprehensive search of PubMed, Cochrane Library, Embase, Web of Science, and ClinicalTrials.gov up to September 2023. Included in the review were studies assessing the efficacy or safety of ERV in treating GNP infections.RESULTSThree randomized controlled trials, seven cohort studies, and two case reports were included. There was no statistically significant difference between ERV and comparators in clinical cure (OR = 0.84, 95% CI = 0.59-1.19), microbiologic eradication (OR = 0.69, 95% CI = 0.36-1.33), and mortality (OR = 1.66, 95% CI = 0.81-3.41). However, a significantly higher rate of adverse events with ERV was observed compared to the control group (OR = 1.55, 95% CI = 1.21-1.99). Additionally, cohort studies reported a clinical cure rate of 73.2% (88.8% in RCTs), an AE rate of 4.5% (38.3% in RCTs), and mortality of 16.2% (1.5% in RCTs). Patients in RCTs received ERV monotherapy, whereas almost half of the patients in cohort studies were treated with ERV in combination with other antibiotics.CONCLUSIONSFurther studies are warranted to investigate the safety and efficacy of ERV monotherapy or combination therapy in critically ill patients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":"35 1","pages":"1-9"},"PeriodicalIF":5.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142187808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating diagnostic tools, outcome measures and antibiotic approach in diabetic foot osteomyelitis: a scoping review and narrative synthesis. 评估糖尿病足骨髓炎的诊断工具、结果测量和抗生素治疗方法：范围界定综述和叙述性综述。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-10 DOI: 10.1080/14787210.2024.2403145

Satwik Motaganahalli,Gemma Reynolds,Suresh Haikerwal,Toby Richards,Trisha N Peel,Jason A Trubiano

引用次数: 0

Alternative drugs for the treatment of gonococcal infections: old and new. 治疗淋球菌感染的替代药物：新旧药物。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-01 Epub Date: 2024-09-10 DOI: 10.1080/14787210.2024.2401560

Susannah Franco, Margaret R Hammerschlag

{"title":"Alternative drugs for the treatment of gonococcal infections: old and new.","authors":"Susannah Franco, Margaret R Hammerschlag","doi":"10.1080/14787210.2024.2401560","DOIUrl":"10.1080/14787210.2024.2401560","url":null,"abstract":"Introduction: The rise in antibiotic resistance to N. gonorrhoeae poses a substantial threat to effective gonorrhea treatment. Historical progression of resistance from sulfonamides to the more recent declines in efficacy of fluoroquinolones and susceptibilities of ceftriaxone highlight the urgent need for novel therapeutic approaches, necessitating the examination of alternative and new antibiotics.Areas covered: This review examines the potential of repurposing older antibiotics for gonorrhea treatment with a focus on their efficacy and limitations. These include aztreonam, ertapenem, and fosfomycin. New oral drugs zoliflodacin and gepotidacin are in late clinical development, but there are concerns regarding their effectiveness for extragenital infections and the development of resistance.Expert opinion: While ceftriaxone remains the best treatment for gonorrhea across all anatomic sites, resistance may eventually limit its use. Among older antibiotics, ertapenem shows the most potential as an alternative but shares the same administrative drawbacks as ceftriaxone. New oral drugs zoliflodacin and gepotidacin initially appeared promising, but their efficacy for pharyngeal infections and potential for resistance development are concerning. Phase 3 trial results have not been made available except through press releases, which perpetuates concerns. Understanding pharmacokinetic and pharmacodynamic profiles of antibiotics will be key in optimizing future treatment recommendations.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"753-759"},"PeriodicalIF":4.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study. 添加铋剂可提高基于替戈普拉赞的两周三联疗法一线根除幽门螺旋杆菌的疗效：一项真实世界证据研究。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-01 Epub Date: 2024-03-13 DOI: 10.1080/14787210.2024.2329251

Jun-Hyung Cho

{"title":"Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study.","authors":"Jun-Hyung Cho","doi":"10.1080/14787210.2024.2329251","DOIUrl":"10.1080/14787210.2024.2329251","url":null,"abstract":"Background: This study aimed to investigate the efficacy of bismuth added to a 2-week triple therapy consisting of tegoprazan (TPZ), amoxicillin, and clarithromycin for first-line Helicobacter pylori eradication.Research design and methods: We reviewed the retrospective data of patients who received a 2-week TPZ-based triple therapy with or without 300 mg bismuth twice daily. The primary endpoint was the H. pylori eradication rate of adding bismuth to the TPZ-based triple regimen (TAC-B group), compared to no bismuth added (TAC group).Results: In total, 306 and 256 patients were included in the intention-to-treat (ITT) and per-protocol (PP) analyses, respectively. The eradication success rates were significantly higher in the TAC-B group than in the TAC group (ITT, 82.9% vs. 71.8%, p = 0.029; PP, 95.8% vs. 87.5%, p = 0.027, respectively). The adherence rate to the eradication regimen was 100% in the TAC-B group and 97.0% in the TAC group. The adverse drug event rate in the TAC-B group was comparable to that in the TAC group (29.2% vs. 27.3%, p = 0.742). No use of bismuth was significantly associated with eradication failure (p = 0.038).Conclusions: The bismuth add-on increased the first-line H. pylori eradication rate of 2-week TPZ-based triple therapy.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05453994.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"793-799"},"PeriodicalIF":4.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140068292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients. 在艾滋病毒合并感染患者中使用泛基因型方案抗病毒治疗 HCV 感染的实际效果。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-01 Epub Date: 2024-05-16 DOI: 10.1080/14787210.2024.2353691

Anna Piekarska, Aleksandra Berkan-Kawińska, Hanna Berak, Włodzimierz Mazur, Marek Sitko, Anna Parfieniuk-Kowerda, Beata Lorenc, Dorota Dybowska, Ewa Janczewska, Justyna Janocha-Litwin, Beata Dobracka, Łukasz Socha, Magdalena Tudrujek-Zdunek, Robert Flisiak

{"title":"Real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients.","authors":"Anna Piekarska, Aleksandra Berkan-Kawińska, Hanna Berak, Włodzimierz Mazur, Marek Sitko, Anna Parfieniuk-Kowerda, Beata Lorenc, Dorota Dybowska, Ewa Janczewska, Justyna Janocha-Litwin, Beata Dobracka, Łukasz Socha, Magdalena Tudrujek-Zdunek, Robert Flisiak","doi":"10.1080/14787210.2024.2353691","DOIUrl":"10.1080/14787210.2024.2353691","url":null,"abstract":"Background: The aim of this study was to evaluate the real-life efficacy of pangenotypic antivirals in HIV-HCV-positive patients.Research design and methods: The analysis included 5650 subjects who were treated with pangenotypic anti-HCV drugs: 5142 were HCV-positive and 508 were HIV-HCV-positive.Results: Patients with HCV-monoinfection were older (p < 0.0001), however patients with HCV-monoinfection had a higher proportion of advanced fibrosis F4 (p < 0.0001). There were no differences between the study groups in the rate of SVR12 in ITT-analysis (87,6% versus 93,9% in coinfection and monoinfection group, respectively; p > 0.05). However, there was a difference between study groups in PP-analysis, HIV/HCV and HCV, respectively 95.9% vs 97.9%, p = 0.0323. Additionally, there were a higher rate of patients who did not apply for follow-up (SVR12) in coinfected patients (7,9% vs 3,6% respectively p = 0.0001). In multivariante analysis, factors associated with worse response to the pangenotypic anti-HCV therapy included male sex, HCV genotype 3, stage of fibrosis and decompensation of liver function and HIV coinfection.Conclusions: The real-life results of pangenotypic anti-HCV treatment are veryeffective in the group of HIV-HCV-coinfected patients. However, the finaleffectiveness is slightly lower than that obtained in HCV monoinfectedpatients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"775-780"},"PeriodicalIF":4.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inflammatory response to SARS-CoV 2 and other respiratory viruses. sars-CoV 2 和其他呼吸道病毒的炎症反应。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-01 Epub Date: 2024-09-11 DOI: 10.1080/14787210.2024.2400548

André Emilio Viñán Garcés, Eder Cáceres, Juan Olivella Gómez, Ignacio Martín-Loeches, Luis Felipe Reyes

{"title":"Inflammatory response to SARS-CoV 2 and other respiratory viruses.","authors":"André Emilio Viñán Garcés, Eder Cáceres, Juan Olivella Gómez, Ignacio Martín-Loeches, Luis Felipe Reyes","doi":"10.1080/14787210.2024.2400548","DOIUrl":"10.1080/14787210.2024.2400548","url":null,"abstract":"Introduction: Lower respiratory tract infections (LRTI) remain a significant global cause of mortality and disability. Viruses constitute a substantial proportion of LRTI cases, with their pandemic potential posing a latent threat. After the SARS-CoV-2 pandemic, the resurgence of other respiratory viruses, including Influenza and Respiratory Syncytial Virus responsible for LRTI has been observed especially in susceptible populations.Areas covered: This review details the inflammatory mechanisms associated with three primary respiratory viruses: SARS-CoV-2, Influenza, and Respiratory Syncytial Virus (RSV). The focus will be on elucidating the activation of inflammatory pathways, understanding cellular contributions to inflammation, exploring the role of interferon and induced cell death in the response to these pathogens and detailing viral evasion mechanisms. Furthermore, the distinctive characteristics of each virus will be explained.Expert opinion: The study of viral pneumonia, notably concerning SARS-CoV-2, Influenza, and RSV, offers critical insights into infectious and inflammatory mechanisms with wide-ranging implications. Addressing current limitations, such as diagnostic accuracy and understanding host-virus interactions, requires collaborative efforts and investment in technology. Future research holds promise for uncovering novel therapeutic targets, exploring host microbiome roles, and addressing long-term sequelae. Integrating advances in molecular biology and technology will shape the evolving landscape of viral pneumonia research, potentially enhancing global public health outcomes.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"725-738"},"PeriodicalIF":4.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nirmatrelvir/ritonavir: real world drug-drug interaction management experience. 尼马瑞韦/利托那韦：真实世界的药物相互作用管理经验。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-22 DOI: 10.1080/14787210.2024.2389884

Shahid Bukhari, Stephen Hughes, Nabeela Mughal, Luke S P Moore, Gary Davies, Adrian Vargas Zhang, Megan Ng, Zekiye Karagozlu, Marta Boffito

引用次数: 0